Related Experiment Videos
First experience with basiliximab in pediatric liver graft recipients
R Ganschow1, D C Broering, I Stuerenburg
1Department of Pediatrics, University Hospital Hamburg Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany. ganschow@uke.uni-hamburg.de
Pediatric Transplantation
|September 19, 2001
Summary
Basiliximab significantly reduces acute graft rejection in pediatric liver transplant patients. This immunosuppressive therapy is safe and effective, showing fewer adverse effects compared to traditional treatments.
Area of Science:
- Immunology
- Transplantation Medicine
- Pediatric Gastroenterology
Background:
- Monoclonal anti-interleukin-2 (IL-2)-receptor antibodies inhibit T-helper cells, reducing acute cellular graft rejection in adults.
- Basiliximab targets the alpha-chain (CD25) of the IL-2 receptor, a key component in T-cell activation.
Purpose of the Study:
- To evaluate the safety and efficacy of basiliximab in pediatric liver transplantation.
- To compare acute graft rejection rates, infectious complications, and adverse effects in children receiving basiliximab versus a historical control group.
Main Methods:
- A pilot study involving 52 pediatric liver transplant recipients.
- Basiliximab group (n=26) received low-dose cyclosporin A (CsA) and basiliximab.
- Control group (n=26) received CsA and prednisolone.
Main Results:
- Significantly lower incidence of acute rejection in the basiliximab group (11.5%) compared to the control group (61.5%).
- Similar rates of infectious complications between the groups.
- Reduced incidence of arterial hypertension, nephrotoxicity, hepatotoxicity, and neurotoxicity in the basiliximab group.
Conclusions:
- Basiliximab in combination with CsA and steroids is safe and effective in reducing acute rejection in pediatric liver transplant recipients.
- Further research is warranted to assess long-term outcomes, including chronic rejection and patient survival.